Please upgrade your browser.
Top-Line Data from METEOR Expected in Q2 2015
Data from the study will be presented during the Plenary Session at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology.
Cincinnati Cancer Center (CCC) researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease, which currently has few treatment options.
The Genentech Access to Care Foundation (GATCF), which provides Genentech medicines for free to people without insurance, is changing its eligibility criteria with the goal of helping more people who may be having trouble accessing Genentech medicines.
When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals.
Renal cells Carcinoma (RCC) Genome variation profiling by genome tiling array with Perkin Elmer Constituionnal Chip platform
Genome variation profiling by genome tiling array
In addition to prostate and lung cancer, Exelixis is testing Cometriq in kidney cancer and liver cancer. Data from the latter trial isn't due until 2017, but the kidney cancer trial, dubbed METEOR, is almost completely enrolled and should read out top-line results in the second quarter of next year.
To investigate discriminating protein patterns and serum biomarkers between clear cell renal cell carcinoma (ccRCC) patients and healthy controls, as well as between paired pre- and post-operative ccRCC patients.
Dr. Voss provides details of a clinical trial that may be of interest to you. The DART study is for patients with metastatic renal cell carcinoma.
First in world to have cancer tumour sequenced
|Powered by NeonCRM|